Microdosing LSD for Alzheimer’s proves safe in early human trial


New results have been published from one of the first placebo-controlled clinical trials investigating the effects of microdosing Lysergic Acid Diethylamide (LSD). This Phase 1 trial is the first step in testing whether these kinds of psychedelic microdose methods could be useful as a therapeutic approach for treating Alzheimer’s disease, and while the early data doesn’t identify significant cognitive benefits in microdosing, it certainly demonstrates the method is safe enough to proceed to larger efficacy trials.

Read full article on NewAtlas.

 

5 Replies to “Microdosing LSD for Alzheimer’s proves safe in early human trial”

  1. We are a group off volunteers and starting a new scheme in our community.
    Youur web site provided us with valuabke info to work on.
    You havbe done an impressive job and our entire communijty will be
    thankful to you.

    My web blog: teen nude

  2. Please let me know if you’re looking for a
    article writer for your blog. You have some really great articles and I believe I would be a good asset.
    If you ever want to take some of the load off, I’d absolutely love to write
    soke material forr your blog in exchange for a link back to mine.

    Please shoot me an e-mail if interested. Cheers!

    Look att mmy blog post … bartlettskennels.co.uk

Leave a Reply

Your email address will not be published.